TY - JOUR
T1 - Influence of R-CHOP therapy on immune system restoration in patients with b-cell lymphoma
AU - Ito, Kaori
AU - Okamoto, Masataka
AU - Inaguma, Yoko
AU - Okamoto, Akinao
AU - Ando, Maiko
AU - Ando, Yosuke
AU - Tsuge, Masahiro
AU - Tomono, Ayana
AU - Kakumae, Yukiko
AU - Hayashi, Takahiro
AU - Yamada, Shigeki
AU - Emi, Nobuhiko
N1 - Publisher Copyright:
© 2016 S. Karger AG, Basel.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Objective: To assess the immunosuppressive effect of R-CHOP in patients with B-cell lymphoma at 2 years. Methods: Parameters of humoral and cell-mediated immunity were assessed in 89 patients with diffuse large B-cell lymphoma or follicular lymphoma before and after 6-8 cycles of R-CHOP-14 or R-CHOP-21 regimen. Results: Data on pre- and posttreatment serum IgG (sIgG) levels were available for all 89 patients, while the corresponding data on serum CD20+, CD3+, CD4+, and CD8+ lymphocyte counts were available in only 43. Median sIgG levels significantly decreased from 1,221 mg/dl (baseline) to 733 mg/dl (after chemotherapy) (p < 0.001). Although CD20+ and CD4+ cell counts decreased (p < 0.001), no significant effect of chemotherapy on CD3+ and CD8+ cell counts was observed. CD20+ cell counts were restored to baseline levels at the 12-month follow-up. sIgG levels and CD4+ cell counts were not completely restored at 24 months, indicating a sustained immunosuppressive effect of R-CHOP in these patients. The incidence of infections over the 2-year period was 16.3-23.6%. Conclusion: The immunosuppressive effect of R-CHOP in newly diagnosed cases of B-cell lymphoma tends to persist for >2 years, although sIgG levels were restored more quickly than CD4+ cell counts.
AB - Objective: To assess the immunosuppressive effect of R-CHOP in patients with B-cell lymphoma at 2 years. Methods: Parameters of humoral and cell-mediated immunity were assessed in 89 patients with diffuse large B-cell lymphoma or follicular lymphoma before and after 6-8 cycles of R-CHOP-14 or R-CHOP-21 regimen. Results: Data on pre- and posttreatment serum IgG (sIgG) levels were available for all 89 patients, while the corresponding data on serum CD20+, CD3+, CD4+, and CD8+ lymphocyte counts were available in only 43. Median sIgG levels significantly decreased from 1,221 mg/dl (baseline) to 733 mg/dl (after chemotherapy) (p < 0.001). Although CD20+ and CD4+ cell counts decreased (p < 0.001), no significant effect of chemotherapy on CD3+ and CD8+ cell counts was observed. CD20+ cell counts were restored to baseline levels at the 12-month follow-up. sIgG levels and CD4+ cell counts were not completely restored at 24 months, indicating a sustained immunosuppressive effect of R-CHOP in these patients. The incidence of infections over the 2-year period was 16.3-23.6%. Conclusion: The immunosuppressive effect of R-CHOP in newly diagnosed cases of B-cell lymphoma tends to persist for >2 years, although sIgG levels were restored more quickly than CD4+ cell counts.
UR - http://www.scopus.com/inward/record.url?scp=84989225427&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84989225427&partnerID=8YFLogxK
U2 - 10.1159/000449251
DO - 10.1159/000449251
M3 - Article
C2 - 27682623
AN - SCOPUS:84989225427
SN - 0030-2414
VL - 91
SP - 302
EP - 310
JO - Oncology (Switzerland)
JF - Oncology (Switzerland)
IS - 6
ER -
